Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Drug Deliv Transl Res. 2013 Aug 1;3(4):336-351.

Nanotechnology for CNS Delivery of Bio-Therapeutic Agents.

Author information

  • 1Department of Pharmaceutical Sciences School of Pharmacy Northeastern University Boston, MA 02115.

Abstract

The current therapeutic strategies are not efficient in treating disorders related to the central nervous system (CNS) and have only shown partial alleviation of symptoms, as opposed to, disease modifying effects. With change in population demographics, the incidence of CNS disorders, especially neurodegenerative diseases, is expected to rise dramatically. Current treatment regimens are associated with severe side-effects, especially given that most of these are chronic therapies and involve elderly population. In this review, we highlight the challenges and opportunities in delivering newer and more effective bio-therapeutic agents for the treatment of CNS disorders. Bio-therapeutics like proteins, peptides, monoclonal antibodies, growth factors, and nucleic acids are thought to have a profound effect on halting the progression of neurodegenerative disorders and also provide a unique function of restoring damaged cells. We provide a review of the nano-sized formulation-based drug delivery systems and alternate modes of delivery, like the intranasal route, to carry bio-therapeutics effectively to the brain.

KEYWORDS:

Central nervous system; bio-therapeutics; blood-brain barrier; drug delivery; intranasal delivery; nano-sized formulations; olfactory receptor neurons; systemic delivery

PMID:
23894728
[PubMed]
PMCID:
PMC3719983
Free PMC Article

Images from this publication.See all images (4)Free text

Figure 1-1
Figure 2-1
Figure 3-1
Figure 4-1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk